Released Feb 1, 2021, before the open
10-K filed Feb 1, 2021, 93 days after period end · 0001654954-21-000973
Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$5.03M$5.03M derived+4.2% vs Q4 2019−20.0% vs Q3 2020
Net Income$144.35K$144.35K derived−69.8% vs Q4 2019−79.1% vs Q3 2020
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$1,357,711−11.7%
Operating Incomederived$151,714−60.9%
Operating Cash Flowderived$336,365N/M
Free Cash Flowderived$330,044N/M
Margins · derived
Gross margin27.0%−4.9 pt vs Q4 2019
Operating margin3.0%−5.0 pt vs Q4 2019
Net margin2.9%−7.0 pt vs Q4 2019
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures | Q4 2017dderived from reported figures |
|---|---|---|---|---|
| Revenue | $5.03M | $4.82M | $5.67M | — |
| Net Income | $144.35K | $477.60K | $3.34M | -$547.03K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR